How does TNGP's PS Ratio compare to its peers?

TNGP is expensive based on its Price-To-Sales Ratio (17.7x) compared to the peer average (6.3x).

How does TNGP's PS Ratio compare vs other companies in the GB Biotechs Industry?

TNGP is expensive based on its Price-To-Sales Ratio (17.7x) compared to the European Biotechs industry average (9x).

What is TNGP's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate TNGP's Price-To-Sales Fair Ratio for valuation analysis.

What is the Fair Price of TNGP when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Insufficient data to calculate TNGP's fair value for valuation analysis.

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

TNGP Stock Overview

A biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. More details

TNGP fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	1/6
Past Performance	0/6
Financial Health	3/6
Dividends	0/6

Rewards

Revenue is forecast to grow 4.43% per year

Risk Analysis

Earnings are forecast to decline by an average of 30.4% per year for the next 3 years

Shares are highly illiquid

Has less than 1 year of cash runway

Currently unprofitable and not forecast to become profitable over the next 3 years

+ 1 more risk

My Notes

Capture your thoughts, links and company narrative

Transgene SA Competitors

Bioventix

AIM:BVXP

UK£165.7m

Oxford Biomedica

LSE:OXB

UK£444.9m

Tissue Regenix Group

AIM:TRX

UK£42.7m

Avacta Group

AIM:AVCT

UK£182.9m

Price History & Performance

Summary of share price highs, lows and changes for Transgene
Historical stock prices
Current Share Price	€1.01
52 Week High	€0
52 Week Low	€0
Beta	0.73
1 Month Change	0%
3 Month Change	-12.62%
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	-48.26%
Change since IPO	-89.29%

Recent updates

Shareholder Returns

	TNGP	GB Biotechs	GB Market
7D	0%	1.4%	0.2%
1Y	n/a	-25.1%	2.3%

Return vs Industry: Insufficient data to determine how TNGP performed against the UK Biotechs industry.

Return vs Market: Insufficient data to determine how TNGP performed against the UK Market.

Price Volatility

Is TNGP's price volatile compared to industry and market?
TNGP volatility
TNGP Average Weekly Movement	n/a
Biotechs Industry Average Movement	10.0%
Market Average Movement	4.7%
10% most volatile stocks in GB Market	10.4%
10% least volatile stocks in GB Market	2.6%

Stable Share Price: TNGP has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine TNGP's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1979	141	Alessandro Riva	www.transgene.fr

Transgene SA, a biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. It involved in developing TG4050, a therapeutic vaccine that is in Phase I clinical trial for the treatment of ovarian cancer, and head and neck cancers; TG4001, a therapeutic vaccine, which is in Phase II clinical trial for the treatment of HPV-positive cancers; TG6002, an oncolytic virus that is in Phase I/IIa clinical trial for the treatment of gastrointestinal and colorectal cancers; and BT-001, an oncolytic virus, which is in Phase I/II clinical trial for the treatment of solid tumors. The company also develops TG1050, a therapeutic vaccine for the treatment of hepatitis B; TG6050 for the treatment of non-small cell lung cancer, and Pexa-Vec, an oncolytic virus for the treatment of solid tumors.

Transgene SA Fundamentals Summary

How do Transgene's earnings and revenue compare to its market cap?
TNGP fundamental statistics
Market cap	€139.91m
Earnings (TTM)	-€22.33m
Revenue (TTM)	€7.90m

17.7x

P/S Ratio

-6.3x

P/E Ratio

Is TNGP overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
TNGP income statement (TTM)
Revenue	€7.90m
Cost of Revenue	€29.59m
Gross Profit	-€21.69m
Other Expenses	€640.00k
Earnings	-€22.33m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

Sep 24, 2024

Earnings per share (EPS)	-0.17
Gross Margin	-274.53%
Net Profit Margin	-282.63%
Debt/Equity Ratio	102.7%

How did TNGP perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/09/14 18:39
End of Day Share Price	2024/06/18 00:00
Earnings	2023/12/31
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Transgene SA is covered by 11 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Olga Smolentseva	Bryan Garnier & Co
Brandon Folkes	Cantor Fitzgerald & Co.
Arsene Guekam	CIC Market Solutions (ESN)

Transgene BATS-CHIXE:TNGP Stock Report